Neuroimaging in Parkinson's Disease

被引：56

作者：

Brooks D.J. ^{[1
]}

机构：

[1] Medical Research Council Clinical Sciences Center, Division of Neuroscience, Faculty of Medicine

来源：

NeuroRX | 2004年 / 1卷 / 2期

关键词：

dopamine; neuroprotection; Parkinson's disease; Positron emission tomography; progression; SPECT;

D O I：

10.1602/neurorx.1.2.243

中图分类号：

学科分类号：

摘要：

In this review, the potential role of positron emission tomography and single photon emission computed tomography as biological markers for diagnosing and following the progression of Parkinson's disease (PD) is discussed. Their value for assessing the efficacy of putative neuroprotective agents in PD and for revealing the pharmacological changes underlying the symptomatology and complications of this disorder is also considered. It is concluded that in the future functional imaging will provide a valuable adjunct to clinical assessment when judging the efficacy of putative neuroprotective approaches to PD. © 2004 The American Society for Experimental NeuroTherapeutics, Inc.

引用

页码：243 / 254

页数：11

共 94 条

[1]

Hu M., White S., Herlihy A., Et al., A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease, Neurology, 56, pp. 1195-1200, (2001)

[2]

Hutchinson M., Raff U., Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging, AJNR Am J Neuroradiol, 21, pp. 697-701, (2000)

[3]

Schrag A., Good C., Miszkiel K., Et al., Differentiation of atypical parkinsonian syndromes with routine MRI, Neurology, 54, pp. 697-702, (2000)

[4]

Schulz J., Skalej M., Wedekind D., Et al., Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy, Ann Neurol, 45, pp. 65-74, (1999)

[5]

Seppi K., Schocke M., Esterhammer R., Et al., Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy, Neurology, 60, pp. 922-927, (2003)

[6]

Jellinger K., The pathology of parkinsonism, Movement disorders 2. Ed 1, pp. 124-165, (1987)

[7]

Fearnley J., Lees A., Ageing and Parkinson's disease: substantia nigra regional selectivity, Brain, 114, pp. 2283-2301, (1991)

[8]

Kish S., Shannak K., Hornykiewicz O., Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease, N Engl J Med, 318, pp. 876-880, (1988)

[9]

Braak H., Tredici K., Rub U., Et al., Staging of brain pathology related to sporadic Parkinson's disease, Neurobiol Aging, 24, pp. 197-211, (2003)

[10]

Jellinger K., Seppi K., Wenning G., Poewe W., Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease, J Neural Transm, 109, pp. 329-339, (2002)

← 1 2 3 4 5 6 7 8 9 10 →